Cartesian Therapeutics, Inc. (RNAC) Operating margin 2016–2025
Cartesian Therapeutics, Inc. (RNAC) operating margin by fiscal year — reported operating income divided by reported revenue.
-35851.2%FY2025 · since FY2016: -428.9% → -35851.2%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -35851.2% | -35736.6 pp |
| FY2024 | -114.7% | +217.6 pp |
| FY2023 | -332.3% | -345.4 pp |
| FY2022 | 13.1% | +18.5 pp |
| FY2021 | -5.4% | +337.0 pp |
| FY2020 | -342.4% | +443.3 pp |
| FY2019 | -785.6% | +6415.1 pp |
| FY2018 | -7200.7% | +23612.9 pp |
| FY2017 | -30813.5% | -30384.6 pp |
| FY2016 | -428.9% | — |
Operating margin = reported operating income ÷ reported revenue for the same fiscal year. Operating-loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More RNAC financial trends
RNAC RevenueRNAC Net incomeRNAC Net marginRNAC Gross profitRNAC Gross marginRNAC Operating incomeRNAC Operating cash flowRNAC Free cash flowRNAC Capital expendituresRNAC Return on equityRNAC Stock buybacksRNAC Dividends paidRNAC Total assetsRNAC Total liabilitiesRNAC Shareholders’ equityRNAC overview →